Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

KTX-1001 will be administered orally, daily for 28 days.

KTX-1001

Soo Bang

Sanjana Miskin

Peter Bergsagel, MD

Daniel Duarte

Alfred Chung, MD

Benjamin Sun

Vivek Roy, MD

Justin Guidry

Sagar Lonial, MD, FACP

Hafsa Ahmed

Al-Ola Abdallah, MD

Lisa Bogart

Andrew Yee, MD

Alicia Marggraf

David Dingli, MD, PhD

Thomas Nelson

David S Siegel, MD, PhD

Adolfo Aleman

Saad Usmani, MD

Leah Gilbert

Saad Usmani, MD, MBA, FACP

Cristina Gasparetto, MD

Heather Griffith

Jesus Berdeja, MD

Sarah Ladd

Aimaz Afrough, MD

Silviya Meletath

Suzanne Trudel, MSc, MD

Saima Dean

Cyrille Touzeau, MD

Laetitia Mallard

Pierre Bories, MD

Alicia Perez

Paula Rodriguez, MD, PhD

Joana Sofia Reis de Carvlaho

Laura Rosinol, MD

Veronica Martil

Laura Rosinol, MD, PhD

Maria-Victoria Mateos Manteca, MD, PhD

Magdalena Garcia Astorga

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

This is a Phase I, open-label, dose escalation and expansion study in adult patients with RRMM.

In the dose escalation phase (Part A), patients will be evaluated for DLTs during Cycle 1 (28 days). The KTX-1001 MTD, RP2D, and schedule will be determined.

In the dose expansion phase (Part B), patients with translocation t(4;14) or a GOF mutation in MMSET (eg, E1099K) will be enrolled. Patients will receive KTX-1001 at the RP2D to further define safety and tolerability and provide preliminary efficacy information.

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma

Treatment-emergent adverse events (AEs), treatment-related AEs, and clinically significant changes in laboratory test results will be evaluated

Per IMWG Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma

K36 Therapeutics, Inc.

Spots Global Cancer Trial Database for t4;14

Every month we try and update this database with for t4;14 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for t4;14

Every month we try and update this database with for t4;14 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for t4;14 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.